Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation
V. Shah, G. Giotopoulos, H. Osaki, M. Meyerhoefer, E. Meduri, B. Schubert, H. Yun, S. J. Horton, S. Agrawal-Singh, P. S. Haehnel, F. Basheer, D. Lugo, M. W. Kuehn, B. Guezguez, M. Theobald, , D. Sasca
This study identifies p300-mediated compensatory transcriptional programs that drive acute resistance to BET inhibitors in AML and suggests sequential BET- and p300-inhibition as a therapeutic strategy.
bioRxiv · Sep 14, 2022 · PreprintCancer Biology